Advertisement

Topics

Search Results for "En Vivo EVP6124 Alzheimer"

19:45 EDT 19th October 2017 | BioPortfolio

Matching Channels

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Histone Deacetylase HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear ...

Nerve growth factor NGF

Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous tissue. NGF and its receptors, the tyrosine-...

Interleukin 1 IL 1 Receptor IL 1R

Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Current therapy targetin...

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

[Articles] Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study

TDP-43 should be considered as a potential factor related to increased rates of hippocampal atrophy in patients with Alzheimer's disease. Given the importance of hippocampal atrophy in Alzheimer's dis...

Microglia turnover with aging and in an Alzheimer's model via long-term in vivo single-cell imaging

Neocortical resident microglia are long-lived cells. Füger et al. report that approximately half of these cells survive for the entire lifespan of a mouse. While microglial proliferation under homeos...

One Doctor's Hopeful Plan To Eradicate Alzheimer's

A new drug developed by Neurogeneticist Dr. Rudolph Tanzi could be part of a cure for Alzheimer's disease within the decade. Tanzi, who co-discovered all three early-onset familial Alzheimer’s genes...

Toward an early Alzheimer's test

Researchers have demonstrated the promise of an early blood test for Alzheimer's disease. The results suggest that Alzheimer's can be detected even before the onset of symptoms in persons at genetic r...

Texcell acquisition of Vivo Science underscores the shifting Biopharma Contract Services landscape

Texcell, a French provider of biosafety contract services, recently acquired German company Vivo Science GmbH, a GLP/GMP compliant contract research test facility specialising in toxicology, immunolog...

New Drug That Could Help Eradicate Alzheimer's Is Ready For Trials

A new drug developed by Neurogeneticist Dr. Rudolph Tanzi could be part of a cure for Alzheimer's disease within the decade. Tanzi, who co-discovered all three early-onset familial Alzheimer’s genes...

Research identifies new brain death pathway in Alzheimer's disease

Alzheimer's disease tragically ravages the brains, memories and ultimately, personalities of its victims. Now affecting 5 million Americans, Alzheimer's disease is the sixth leading cause of death in ...

ASU/Biodesign researchers enter race for early Alzheimer's test

(Arizona State University) In a new study, Paul Coleman and his colleagues demonstrate the promise of an early blood test for Alzheimer's disease. The results suggest that Alzheimer's can be detected...

Matching PubMed Articles

Association of In Vivo 18FAV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.

Previous postmortem studies have long demonstrated that neurofibrillary tangles made of hyperphosphorylated tau proteins are closely associated with Alzheimer disease clinical phenotype and neurodegen...

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated β-amyloid.

Sensitive detection of cognitive decline over the course of preclinical Alzheimer's disease is critical as the field moves toward secondary prevention trials.

Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial MRI study.

Identifying at what point atrophy rates first change in Alzheimer's disease is important for informing design of presymptomatic trials.

The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: An EADC study.

Hippocampal volume is a core biomarker of Alzheimer's disease (AD). However, its contribution over the standard diagnostic workup is unclear.

In vivo biosynthesized zinc and iron oxide nanoclusters for high spatiotemporal dual-modality bioimaging of Alzheimer's disease.

Alzheimer's disease is still incurable neurodegenerative, and lack of detection method with high sensitivity and specificity. In this study, by taking different month old Alzheimer's mice as models, w...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement